{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihra7eo2euj6ojxth3phpyytwh6dkdupxi2hr4c6etauljoccedty",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkfp7ccuujo2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidjzwhji6o3ivakly67mexdwukp7nk5ho3izgufxzxsm2gwbcrdzm"
    },
    "mimeType": "image/jpeg",
    "size": 361961
  },
  "path": "/news/2026-04-discovery-vulnerability-aggressive-lymphoma-future.html",
  "publishedAt": "2026-04-26T08:00:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can be used to override the defenses of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. These defenses often cause treatments to be ineffective because they allow the cancer cells to survive. The results are especially relevant to ABC-DLBCL, a specific subtype of blood cancer that has poor patient prognosis and survival outcome. The new study appeared under the title \"Expression of cFLIP in B cells is essential for diffuse large B cell lymphoma pathogenesis\" in the Blood Journal.",
  "title": "Discovery of a novel vulnerability in aggressive lymphoma could change future therapy"
}